Biomarker Kit for Metastatic Breast Cancer Prognosis and Uses Thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jun 15, 2017
filing date -
Jun 15, 2016
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided herein are kits for detecting and quantifying the level of a metastatic cancer biomarker(s) in a patient. The kits may contain a detection and quantifying means, such as, biomarker specific antibodies. Also provided are methods for determining a prognosis, a stratification and/or monitoring of a metastatic cancer in a patient. The level or activity of at least two biomarkers, such as obscurin, PI3K, E-cadherin, or N-cadherin is measured in a patient sample and compared to corresponding biomarkers in a control sample. A significant difference in the level or activity of the biomarkers between the patient sample and control is indicative of a metastatic cancer. In addition a method for treating a metastatic breast cancer via administration of a PI3K inhibitor and an agent that increases expression of obscurin is provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully